Celldex At A Loss To Explain Why Brain Cancer Vaccine Rintega Failed Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Rintega performed as usual in Phase III ACT IV study, but comparator arm Temodar was much better than in prior trials, for unknown reasons.